European private equity outfit Cinven has stepped up to buy the majority of long-rumored target Medpace, trading $915 million for an undisclosed controlling stake in the CRO.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
SAN FRANCISCO--Another J.P. Morgan Healthcare Conference is in the books, and biopharma's movers, shakers and up-and-comers have headed back to Boston, Basel and Bangalore. This year, in the shadow of the best market for biotech IPOs since 2000, there's fresh optimism that capital will continue to flow into drug developers' pockets, whether via more market debuts or through the many top-tier VCs putting together new funds.
To no one's surprise, cancer immunotherapies are hogging much of the spotlight, but Intercept's explosive week put NASH near the top of the list of biopharma buzzwords, and a host of promising RNA therapies from companies big and small grabbed some headlines. Through it all, the Fierce team was darting in and out of presentations, one-on-ones and cafe chats in and around Union Square to bring you this, our annual industry barometer.
POPULAR COMMENT THREADS
Global CRO Covance boosted its revenue by about 11% last quarter, capping off a banner year in which the company outstripped its financial targets.
INC Research is doubling down on the Middle East, buying up a longtime partner to tighten its grip on a region the CRO says is rapidly developing into a go-to market for clinical research.
WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.
Early-phase CRO Celerion is expanding its reach into South Korea, partnering up with a local hospital to run trials in the country's fast-growing market for clinical research.
Indiana's Harlan Laboratories has struck up a deal with French CRO Bertin Pharma to pool resources on early development, teaming up to offer drug discovery and translational medicine services.
Netherlands' CRO Cardialysis has reached out to Boston eClinical outfit AG Mednet to oversee data submission and collection for the medical device and drug trials it runs at more than 1200 sites around the world.
From Our Sister Sites
Announced earlier this week, President Barack Obama's proposed budget for 2015 includes $30.4 billion for the National Institutes of Health, a slight increase of $211 million over this fiscal year's budget.
Some of the leaders in the frenzied late-stage race to develop a PCSK9 drug watched their stock prices stumble on Friday afternoon as word of the FDA's concern about potential neurocognitive side effects in the cholesterol drug class ripped through Twitter.